Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy

Background: Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin,...

Full description

Saved in:
Bibliographic Details
Main Authors: K. Sugiyama, S. Kumar, A. Chaudry, N. Patel, P. Patel, D. Cunningham, N. Starling, S. Rao, C. Fribbens, L. Eldridge, I. Chau
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:ESMO Gastrointestinal Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2949819825000925
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849390490942701568
author K. Sugiyama
S. Kumar
A. Chaudry
N. Patel
P. Patel
D. Cunningham
N. Starling
S. Rao
C. Fribbens
L. Eldridge
I. Chau
author_facet K. Sugiyama
S. Kumar
A. Chaudry
N. Patel
P. Patel
D. Cunningham
N. Starling
S. Rao
C. Fribbens
L. Eldridge
I. Chau
author_sort K. Sugiyama
collection DOAJ
description Background: Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment. Materials and methods: We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria. Results: A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, P < 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, P < 0.001). A decreased PNI (P = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, P = 0.75). Conclusions: Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.
format Article
id doaj-art-6985ef87d140481eb160b60417d77bea
institution Kabale University
issn 2949-8198
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series ESMO Gastrointestinal Oncology
spelling doaj-art-6985ef87d140481eb160b60417d77bea2025-08-20T03:41:36ZengElsevierESMO Gastrointestinal Oncology2949-81982025-09-01910022310.1016/j.esmogo.2025.100223Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapyK. Sugiyama0S. Kumar1A. Chaudry2N. Patel3P. Patel4D. Cunningham5N. Starling6S. Rao7C. Fribbens8L. Eldridge9I. Chau10Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, UK; Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya, Aichi, JapanDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UKDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UKDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UKDepartment of Upper Gastrointestinal Surgery, The Royal Marsden Hospital, London, UKGastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, UKGastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, UKGastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, UKGastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, UKDepartment of Nutrition &amp; Dietetics, The Royal Marsden Hospital, London, UKGastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, UK; Correspondence to: Prof. Ian Chau, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK. Tel: +44-208-915-6196Background: Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment. Materials and methods: We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria. Results: A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, P < 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, P < 0.001). A decreased PNI (P = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, P = 0.75). Conclusions: Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.http://www.sciencedirect.com/science/article/pii/S2949819825000925FLOTgastric cancermalnutritionoesophageal cancerperioperative therapy
spellingShingle K. Sugiyama
S. Kumar
A. Chaudry
N. Patel
P. Patel
D. Cunningham
N. Starling
S. Rao
C. Fribbens
L. Eldridge
I. Chau
Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy
ESMO Gastrointestinal Oncology
FLOT
gastric cancer
malnutrition
oesophageal cancer
perioperative therapy
title Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy
title_full Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy
title_fullStr Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy
title_full_unstemmed Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy
title_short Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy
title_sort impact of nutritional status on pathological response and recurrence free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative flot therapy
topic FLOT
gastric cancer
malnutrition
oesophageal cancer
perioperative therapy
url http://www.sciencedirect.com/science/article/pii/S2949819825000925
work_keys_str_mv AT ksugiyama impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT skumar impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT achaudry impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT npatel impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT ppatel impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT dcunningham impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT nstarling impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT srao impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT cfribbens impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT leldridge impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy
AT ichau impactofnutritionalstatusonpathologicalresponseandrecurrencefreesurvivalinlocallyadvancedoesophagogastricadenocarcinomatreatedwithperioperativeflottherapy